Tepotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tepotinib
Accession Number
DB15133
Description

Tepotinib is under investigation in clinical trial NCT03531762 (Effect of a Proton Pump Inhibitor on the Pharmacokinetics (PK) of Tepotinib).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 492.583
Monoisotopic: 492.227374166
Chemical Formula
C29H28N6O2
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
1IJV77EI07
CAS number
1100598-32-0
InChI Key
AHYMHWXQRWRBKT-UHFFFAOYSA-N
InChI
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
IUPAC Name
3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile
SMILES
CN1CCC(COC2=CN=C(N=C2)C2=CC(CN3N=C(C=CC3=O)C3=CC(=CC=C3)C#N)=CC=C2)CC1

References

General References
Not Available
ChemSpider
28637823
BindingDB
50065457
ChEMBL
CHEMBL3402762
ZINC
ZINC000043202335
PDBe Ligand
3E8
Wikipedia
C-Met_inhibitor
PDB Entries
4r1v

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentNeoplasms, Colorectal1
2RecruitingTreatmentAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations or MET Amplification1
2RecruitingTreatmentMET Amplification / MET exon 14 skipping mutation / Tumors, Solid1
2RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedOtherHealthy Volunteers5
1CompletedOtherHepatic Impairment1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPatients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available1
1, 2Active Not RecruitingTreatmentHepatocellular Carcinoma1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00999 mg/mLALOGPS
logP3.64ALOGPS
logP4ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.13ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area94.71 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity154.74 m3·mol-1ChemAxon
Polarizability54 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:52 / Updated on June 12, 2020 10:53